Evidence map›Paper›PMID 23939902›Full record

ArticleAntimicrobial agents and chemotherapy2013

Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro.

Faseeha Noordeen, Andrew Vaillant, Allison R Jilbert

5 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02233075 phase2completednot on this mapstarted 2014, after this paper: background citation

A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infection

TypeinterventionalSponsorReplicor Inc.Ran2014 to 2017Enrolled12ConditionsChronic HBV Infection (HBeAg Negative)ArmsREP 2139-Ca + Pegasys (TM)
NCT02565719 phase2completednot on this mapstarted 2016, after this paper: background citation

An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B

TypeinterventionalSponsorReplicor Inc.Ran2016 to 2019Enrolled40ConditionsChronic Hepatitis BArmsREP 2139-Mg, Pegasys, Viread, REP 2165-Mg
NCT02646163 phase1 / phase2completednot on this map

Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

TypeinterventionalSponsorReplicor Inc.Ran2009 to 2012Enrolled8ConditionsHepatitis B, ChronicArmsREP 2055
NCT02646189 phase1 / phase2completednot on this map

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

TypeinterventionalSponsorReplicor Inc.Ran2011 to 2013Enrolled12ConditionsHepatitis B, ChronicArmsREP 2139-Ca, Zadaxin, Pegasys
NCT02726789 phase2completednot on this map

Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

TypeinterventionalSponsorReplicor Inc.Ran2012 to 2016Enrolled5ConditionsHepatitis B, ChronicArmsREP 2139-Ca, pegylated interferon, entecavir
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 56 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Editorial:Molecular therapy. Nucleic acids · 2022
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Faseeha NoordeenSchool of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia.
Andrew Vaillant
Allison R Jilbert
University of Adelaide · AUUniversity of Peradeniya · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nucleic acid polymers (NAPs) utilize the sequence-independent properties of phosphorothioate oligonucleotides (PS-ONs) to target protein interactions involved in viral replication. NAPs are broadly active against a diverse range of enveloped viruses that use type I entry mechanisms. The antiviral activity of NAPs against hepatitis B virus (HBV) infection was assessed in vitro in duck hepatitis B virus (DHBV)-infected primary duck hepatocytes (PDH). NAPs efficiently entered PDH in the absence of any transfection agent and displayed antiviral activity at concentrations of 0.01 to 10 μM, measured by their ability to prevent the intracellular accumulation of DHBV surface antigen, which was independent of their nucleotide sequence and was specifically dependent on phosphorothioation. Higher levels of antiviral activity were observed with NAPs 40 nucleotides in length or longer. The fully degenerate NAP (REP 2006) was active during DHBV infection or when added 12 h after infection. In contrast, an acidic-pH-sensitive NAP (REP 2031) that was broadly active against other viruses displayed antiviral activity when present during DHBV infection but no activity when added 12 h after infection, suggesting that NAPs exert their postentry effect in an acidic environment unique to DHBV infection. Both REP 2006 and REP 2031 displayed negligible cytotoxicity in PDH at concentrations of up to 10 μM, as assessed using an XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cytotoxicity assay. The antiviral activity of NAPs against DHBV in vitro was strictly dependent on their amphipathic character, suggesting that NAPs interact with amphipathic target(s) that are important for DHBV entry and postentry mechanisms required for infection.

Indexed as

AnimalsAntiviral AgentsCell SurvivalHepatitis B Surface AntigensHepatitis B Virus, DuckHepatocytesHydrogen-Ion ConcentrationHydrophobic and Hydrophilic InteractionsPhosphorothioate OligonucleotidesPrimary Cell CultureStructure-Activity RelationshipVirus InternalizationVirus ReplicationAntiviral AgentsHepatitis B Surface AntigensPhosphorothioate Oligonucleotides

Identifiers

PMID23939902
PMCPMC3811297
OpenAlexW1967083475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.